Dr. Lbiati is a biopharma business leader and independent board director focused on innovation, value creation, and broadening patients’ access to transformative technologies and healthcare delivery. She currently sits on two public boards at Hepion Pharmaceuticals (Nasdaq: HEPA) and Theralase Technologies (TSXV: TLT).
With a career spanning five countries (France, United Arab Emirates, United Kingdom, United States, and Canada) over the past two decades, she has held several leadership positions at some of the world’s leading pharmaceutical companies and early- and late-stage public and private biotechs. Across her roles within corporate strategy, business development, strategic planning, health economics and outcomes research, market access, and global medical affairs, she supported the registration and/or launch of six innovative medicines that reached millions of patients around the world.
Her leadership was critical for the clinical, commercial, and economic evaluations of medical technologies, while it also enabled sound value propositions resulting in strategic partnerships and business development deals including joint ventures and mergers. She has served as a strategic advisor to venture capital firms and consulted for think tanks, focusing on organizational healthcare systems, industrial healthcare policy, digital healthcare transformation, and entrepreneurship in middle-income countries. A regular contributor to policy papers, international outlets, and multidisciplinary panels, she is fluent in English, French, and Arabic.
Dr. Lbiati received a Doctor of Medicine degree from Morocco’s Mohammed V University, completed a fellowship in Oncology at Institut Gustave Roussy in Paris, earned a specialized Master’s degree in Strategy and Management from ESSEC Business School in Paris, and a Master of Science in International Policy and Health Economics from the London School of Economics. She is also certified in Finance (Harvard Business School) and Corporate Governance (Columbia Business School).
